Why Avalon GloboCare Corp. Could Be the Next Golden Ticket

Clinical Advances in Immuno-Oncology Through a Technology + Service Ecosystem

It's often said that "where there's smoke, there's fire." Well, $AVCO is putting off Vesuvius-level smoke through strategic advisement and outsourcing to clients in both domestic and global health care systems.

Price Targets


< 1 WK


< 2 WKS


> 1 MO

Don't miss our analysis with charts, price targets, entries, and a quick look at this exciting company.

Once-in-a-blue-moon entries at firesale prices

Potential to triple your investment with the right setup

The trinity of indicators: volume inflow, bullish divergence, descending wedge breakout imminent

Sector & company expected to outperform over next 6 months

Chart Analysis

Why We Love the Setup

Biotech has gone further into oversold territory than any other sector since early 2021. When we research companies with bullish outlook, we want to see potential upside that will surpass other sectors, and this company shows that potential, making it a strong contender from now through 2023 and giving $AVCO a leg up on the market.

There is an incredible risk-reward ratio here for this price point. Potential shows a 50-percent gain over the next few days to weeks as well as a 100-percent gain over the next six months.

Some observations:

  • RSI bullish divergence on the hourly chart
  • Last two strong pushes off the $0.40 area bounce; we tested $0.62 to $0.81 (50-percent possible potential)
  • 9 EMA bullish crossover on hourly chart
  • Testing break of the 200ema on the four-hour chart
  • MACD golden cross on daily chart

Key Partnerships

Massachusetts Institute of Technology
University of Pittsburgh
Weill Cornell Medicine

Mission Statement

"Avalon GloboCare Corp. (Nasdaq: $AVCO) is a clinical-stage biotechnology company dedicated to develop and deliver innovative and transformative CellTech with multifunctional convergence in cellular technologies/therapeutics, precision diagnostics and intellectual property in the field of immuno-oncology and cellular medicines."

So what does that mean?

$AVCO has created a multifunctional system that has identified far superior and safer Therapeutic Options, while cutting bio manufacturing time and costs, with an incredible uptick in patient accessibility and a vast group of International Multi Center Clinical Trials.

Avalon GloboCare Corp
Virus cell
Red blood cells
Lab technician looking into a microscope

Things You Need to Know About

Avalon GloboCare Corp.

  • There are currently two clinical trials active on AVA 001 and AVA 011 with both Chinese and USA FDA streamlined.
  • In clinical trials with anti-CD19 CAR-T and transitioning into human trials for cancer (leukemia) treatments. We expect this to have a profound impact on future cancer research and treatments.
  • Studying AI applications to accelerate development of Monoclonal Antibodies.
  • $AVCO currently has 16 patent applications filed with co-inventors and key strategic partners.
  • Headquartered in the 'Silicon Valley of biotech' with 70 FDA approvals in the past two years.
  • 63-percent of shares owned by insiders, leading to a bullish sentiment across institutions.
  • Maintaining a steady foundation in medical consulting, research studies, advisory board services, and management services in immunotherapy, which demonstrates stability and a strong foothold within the volatile biotech sector.
  • Clinical trials expected to generate speculative interest.


1 of 25 selected members of ASTCT’s Corporate Council

Allowance for Joint US Patent, September 2022

Announcement* of QTY Code Technology, August 2022


* Published in Journal of the American Chemical Society

Avalon GloboCare's leadership


Avalon GloboCare Corp. is a leading clinical-stage CellTech bio-developer dedicated to (1) advancing and empowering innovative, transformative immune effector cell therapy, and (2) exosome technology.

Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth, development, as well as competitiveness in healthcare and CellTech industry markets.

Avalon’s subsidiary and joint venture structure contribute to investor flexibility and R&D focus, enabling Avalon to establish our leading role in the fields of immune effector cell therapy (including CAR-T and CAR-NK), exosome-based regenerative therapeutics (our ACTEXTM platform), as well as "liquid biopsy" diagnostics.

David Jin, M.D., Ph.D., AVCO

CEO, President

Avalon GloboCare Corp
Meng Li


Luisa Ingargiola, CFO, AVCO
Luisa Ingargiola


Looking for even more information?


Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage .We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Virtus Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers' works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer's communications regarding the profiled company(s). You should assume all information in all of our communications in incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Compensation: Pursuant to an agreement between Virtus Media LLC and Lifewater Media, Virtus Media LLC has been hired for a period of five business days beginning on 10/17/22 and ending on 10/21/22 to publicly disseminate information about (NASDAQ:AVCO) via digital communications. We have been paid twenty thousand USD via ACH Bank Transfer. Pursuant to an agreement between Virtus Media LLC and Lifewater Media, Virtus Media LLC has been hired for a period beginning on 11/4/22 and ending after five business days to publicly disseminate information about (NASDAQ: AVCO) via digital communications. We have been paid twelve thousand five hundred USD via ACH Bank Transfer. Social Media Compensation: Pursuant to an agreement between Virtus Media LLC and Social Media Outlet, Virtus Media LLC has hired Social Media Outlet for a period beginning on 10/17/22 and ending after five business days to publicly disseminate information about (NASDAQ:AVCO) via digital communications. We have paid this Social Media Outlet five thousand USD via ACH Bank Transfer.